Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial
Lee YJ, Cho JY, You SC, et al.
European Heart Journal. ehac709.
Leggi
Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century
Lazzarini PA, Cramb SM, Golledge J, et al.
Diabetologia. Pub. online 13 Dec 2022.
Leggi
MiniMed 780G™ in 2–6-year-old children: safety and clinical outcomes after the first 12 weeks
Pulkkinen MA, Varimo T, Hakonen ET, et al.
Diabetes Technol Ther. Pub. online 13 Dec 2022.
Leggi
GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes
Marx N, Husain M, Lehrke M, et al.
Circulation. 2022;146:1882-1894.
Leggi
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino T, Alexander CM, Amiel SA, et al.
The Lancet Diabetes and Endocrinology. Pub. online, 6 December 2022.
Leggi
Initiation of sodium-glucose cotransporter-2 inhibitors at lower HbA1c threshold attenuates eGFR decline in type 2 diabetes patients with and without cardiorenal disease: A propensity-matched cohort study
Cheung JTK, Yang A, Wu H, et al.
Diabetes Res Clin Pract. Pub. online 6 Dec 2022.
Leggi
Two decades of diabetes prevention efforts: a call to innovate and revitalize our approach to lifestyle change
Golovaty I, Ritchie ND, Tuomilehto J, et al.
Diabetes Res Clin Pract. 2022;110195.
Leggi
Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering
Mistry S, Gouripeddi R, Raman V, Facelli JC
Diabetologia. 2022 Nov 30.
Leggi
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Urva S, Coskun T, Loh MT, et al.
Lancet. 2022;400(10366):1869-1881.
Leggi
Comparison of sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist prescribing in patients with diabetes mellitus with and without cardiovascular disease
Gay HC, Yu J, Persell SD, et al.
Am J Cardiol. 2022;S0002-9149(22)01131-6.
Leggi